Health-related quality of life, symptoms, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma

Researchers analyzed the health-related quality of life, symptoms, and tolerability data from the phase 2 LOTIS-2 trial involving patients receiving loncastuximab tesirine for relapsed/refractory DLBCL. In their findings, EQ VAS overall health scores improved during treatment, and FACT-Lym total scores remained stable. Patients reported improvement from baseline in pain, lumps/swelling, and losing weight. More than 60% of patients were not bothered or only bothered "a little bit" by treatment side effects.